Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leqvio subcutaneous injection post-marketing drug-use survey in Japanese patients with familial hypercholesterolaemia or hypercholesterolaemia
jRCT2031230654Recruiting
- Sponsor
- Novartis
- Start
- Mar 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of inclisiran in familial hypercholesterolemia (FH) and hypercholesterolemia, sponsored by Novartis. Primary endpoints: Number and percentage of patients with adverse events, Number and percentage of patients with serious adverse events and 2 more. Started Mar 2024; status: recruiting.
02
Drugs
inclisiran
03
Conditions
familial hypercholesterolemia (FH)hypercholesterolemia
Beyond the preview
Go deeper on jRCT2031230654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230654.